CAR immune cells: design principles, resistance and the next generation

L Labanieh, CL Mackall - Nature, 2023 - nature.com
The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …

Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours

CL Flugel, RG Majzner, G Krenciute, G Dotti… - Nature Reviews …, 2023 - nature.com
Therapies with genetically modified T cells that express chimeric antigen receptors (CARs)
specific for CD19 or B cell maturation antigen (BCMA) are approved to treat certain B cell …

PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial

V Narayan, JS Barber-Rotenberg, IY Jung, SF Lacey… - Nature medicine, 2022 - nature.com
Chimeric antigen receptor (CAR) T cells have demonstrated promising efficacy, particularly
in hematologic malignancies. One challenge regarding CAR T cells in solid tumors is the …

Navigating CAR-T cells through the solid-tumour microenvironment

AJ Hou, LC Chen, YY Chen - Nature reviews Drug discovery, 2021 - nature.com
The adoptive transfer of T cells that are engineered to express chimeric antigen receptors
(CARs) has shown remarkable success in treating B cell malignancies but only limited …

Intraventricular B7-H3 CAR T cells for diffuse intrinsic pontine glioma: preliminary first-in-human bioactivity and safety

NA Vitanza, AL Wilson, W Huang, K Seidel, C Brown… - Cancer discovery, 2023 - AACR
Diffuse intrinsic pontine glioma (DIPG) remains a fatal brainstem tumor demanding
innovative therapies. As B7-H3 (CD276) is expressed on central nervous system (CNS) …

GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas

RG Majzner, S Ramakrishna, KW Yeom, S Patel… - Nature, 2022 - nature.com
Diffuse intrinsic pontine glioma (DIPG) and other H3K27M-mutated diffuse midline gliomas
(DMGs) are universally lethal paediatric tumours of the central nervous system. We have …

Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis

NA Vitanza, AJ Johnson, AL Wilson, C Brown… - Nature medicine, 2021 - nature.com
Locoregional delivery of chimeric antigen receptor (CAR) T cells has resulted in objective
responses in adults with glioblastoma, but the feasibility and tolerability of this approach is …

B7-H3/CD276: an emerging cancer immunotherapy

WT Zhou, WL ** - Frontiers in immunology, 2021 - frontiersin.org
Immunotherapy aiming at suppressing tumor development by relying on modifying or
strengthening the immune system prevails among cancer treatments and points out a new …

Next-generation CAR T-cell therapies

RM Young, NW Engel, U Uslu, N Wellhausen, CH June - Cancer discovery, 2022 - AACR
CD19-and B-cell maturation antigen (BCMA)–directed chimeric antigen receptor (CAR) T
cells have enabled unprecedented responses in a subset of refractory patients with B-cell …

[HTML][HTML] GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity

S Heitzeneder, KR Bosse, Z Zhu, D Zhelev… - Cancer Cell, 2022 - cell.com
Pediatric cancers often mimic fetal tissues and express proteins normally silenced
postnatally that could serve as immune targets. We developed T cells expressing chimeric …